Brugada syndrome masked by complete left bundle branch block
Abbas Hoteit MD, Marwan M. Refaat, MD
Division of Cardiology, Department of Internal Medicine, American
University of Beirut Medical Center, Beirut, Lebanon
Running Title: Brugada Syndrome masked by LBBB
Words: 741 (excluding the title page and references)
Keywords: Brugada syndrome, Left bundle branch block, Cardiovascular
Diseases, Heart Diseases, Cardiac Arrhythmias
Funding: None
Disclosures: None
Corresponding Author:
Marwan M. Refaat, MD, FACC, FAHA, FHRS, FASE, FESC, FACP, FAAMA
Associate Professor of Medicine
Director, Cardiovascular Fellowship Program
Department of Internal Medicine, Cardiovascular Medicine/Cardiac
Electrophysiology
Department of Biochemistry and Molecular Genetics
American University of Beirut Faculty of Medicine and Medical Center
PO Box 11-0236, Riad El-Solh 1107 2020- Beirut, Lebanon
US Address: 3 Dag Hammarskjold Plaza, 8th Floor, New York, NY 10017, USA
Office: +961-1-350000/+961-1-374374 Extension 5353 or Extension 5366
(Direct)
Brugada syndrome is a genetic disorder that affects the electrical
activity of the heart. It is characterized by ST-segment elevations in
the right precordial leads and right bundle branch morphology on
ECG.1 These ECG changes are present in the absence of
other causes of ST elevation or right bundle branch block morphology
such as structural heart disease, ischemia, pacing or electrolyte
disturbances.2 Clinical presentation varies between
patients; it can range from asymptomatic changes seen on ECG to syncope,
ventricular arrhythmias, and sudden cardiac death. 3So far, three types of ECG repolarization patterns have been identified
(type 1, type 2, and type 3).4 Type 1 pattern is
diagnostic of Brugada syndrome whereas types 2 and 3 are considered
suggestive.5 According to the 2016 consensus
conference of J-wave syndromes, the diagnosis of Brugada syndrome can
only be made by finding a type 1 repolarization pattern. A type 1
pattern can either be spontaneous or unmasked by fever or medications.
If it has been unmasked by either, then further evidence of patient
clinical history, family history, or genetic testing should be present
to fulfill a score of 3.5 or higher according to the Shanghai Scoring
System.6 7 The Shanghai Scoring System does not
include imaging; hence, even if changes in the right ventricle are found
on cardiac MRI, they play no role in the diagnosis. 7In patients presenting with a non-type 1 pattern, a sodium channel
blocker challenge is frequently used to unmask the type 1 pattern.
Unmasking this pattern allows for diagnosis of Brugada syndrome which
has a big impact on prognosis and management options. In some patients,
an initial flecainide challenge test may be negative due to the variable
sensitivity of this test. Some studies have shown that repeating the
test may increase sensitivity, but, with increased risk of adverse drug
effects. Prasad et al. showed that in patients with high clinical
suspicion, family history of sudden cardiac death could serve as an
indicator to repeat the flecainide test.5 8 9
Several possible risk factors, that might predispose individuals to have
a more severe presentation, have been identified. These include male
gender, history of syncope, spontaneous type 1 pattern, family history
of Brugada syndrome, and loss-of-function mutations in the SCN5A gene
(which codes the alpha subunit of the cardiac sodium channel).10 Patients with SCN5A mutations tend to have earlier
onset of symptoms, more noticeable electrophysiological defects (such as
sick sinus syndrome and AV blocks), and increased risk of major
arrhythmic events especially in Asian and Caucasian populations.11 High-risk patients are susceptible to sudden
cardiac death; therefore, risk stratification helps in patient selection
for Implantable Cardioverter Defibrillator placement.12 13
In their article, Eduardo et al. presented the case of a 48-year-old
lady who was initially diagnosed with Brugada syndrome after having a
type 1 pattern on ECG. During follow-up, the patient’s ECG changed and
showed a complete left bundle branch block instead of the typical type 1
pattern. Molecular studies showed the novel SCN5A p.1449Y>H
variant and subsequent functional analysis showed a nonfunctional
mutated membrane channel. SCN5A mutation can cause Brugada syndrome and
conduction system abnormality as described in this lady. This variant
generated minimal sodium currents. Such major decrease in current
magnitude is associated with high penetrance as seen in the cases in
this study. Although, during close follow-up, these patients did not
have severe symptoms.14 What is most significant is
that the authors presented a patient with Brugada syndrome who
subsequently developed findings of complete left bundle branch block on
ECG, making the diagnosis challenging due to masking of the type 1
pattern. This opens further discussion about diagnosis of the syndrome
and potential maneuvers or procedures that would help unmask type 1
pattern under heart block. Since diagnosis can only be made by
witnessing this pattern, this presents us a possibility where a
diagnosis would be missed in such patients. SCN5A is the most common
gene associated with this syndrome, accounting for around 20%. However,
patient presentation varies widely with different mutations affecting
channel function differently. In this case, the p.1449Y>H
variant showed high penetrance and channel dysfunction despite
relatively non-severe symptoms in patients affected. However, further
observation is warranted to assess progression of the disease and the
incidence of major arrhythmogenic events with aging and subsequent
fibrosis. Further research is required to investigate the role of
genetic studies in risk stratification and projecting patient clinical
course depending on the presence of specific gene mutations/variants.
References:
- Refaat MM, Hotait M, Scheinman MM. Brugada Syndrome. Card
Electrophysiol Clin Mar 2016; 8(1): 239-45.
- Refaat M, Mansour M, Singh JP, Ruskin JN, Heist EK.
Electrocardiographic Characteristics in Right Ventricular Versus
Biventricular Pacing in Patients With Paced Right Bundle Branch Block
QRS Pattern. J Electrocardiol Mar-Apr 2011; 44 (2): 289-95.
- Tse G, Liu T, Li KH, et al. Electrophysiological mechanisms of Brugada
syndrome: insights from pre-clinical and clinical studies. Front
Physiol 2016; 7: 467.
- Wilde, A. a. M.; Antzelevitch, C.; Borggrefe, M.; Brugada, J.;
Brugada, R.; Brugada, P.; Corrado, D.; Hauer, R. N. W.; Kass, R. S.;
Nademanee, K.; Priori, S. G. (November 2002). ”Proposed diagnostic
criteria for the Brugada syndrome”. European Heart
Journal . 23 (21): 1648–1654.
- Prasad S, Namboodiri N, Thajudheen A, Singh G, Prabhu MA, Abhilash SP,
Mohanan Nair KK, Rashid A, Ajit Kumar VK, Tharakan JA. Flecainide
challenge test: Predictors of unmasking of type 1 Brugada ECG pattern
among those with non-type 1 Brugada ECG pattern. Indian Pacing
Electrophysiol J. 2016 Mar-Apr;16(2):53-58. doi:
10.1016/j.ipej.2016.06.001. Epub 2016 Jun 20. PMID: 27676161; PMCID:
PMC5031807.
- Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert
consensus conference report: emerging concepts and gaps in knowledge.Heart Rhythm 2016;13:e295-324.
- Vutthikraivit W, Rattanawong P, Putthapiban P, Sukhumthammarat W,
Vathesatogkit P, Ngarmukos T, Thakkinstian A. Worldwide Prevalence of
Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol
Sin. 2018 May;34(3):267-277. doi: 10.6515/ACS.201805_34(3).20180302B.
Erratum in: Acta Cardiol Sin. 2019 Mar;35(2):192. PMID: 29844648;
PMCID: PMC5968343.
- Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P,
Ceriotti C, Simonini S. Flecainide test in Brugada syndrome: a
reproducible but risky tool. Pacing Clin Electrophysiol. 2003
Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x. PMID:
12687841.
- Dubner S, Azocar D, Gallino S, Cerantonio AR, Muryan S, Medrano J,
Bruno C. Single oral flecainide dose to unmask type 1 Brugada syndrome
electrocardiographic pattern. Ann Noninvasive Electrocardiol. 2013
May;18(3):256-61. doi: 10.1111/anec.12052. PMID: 23714084; PMCID:
PMC6932426.
- Bayoumy A, Gong MQ, Christien Li KH, Wong SH, Wu WK, Li GP, Bazoukis
G, Letsas KP, Wong WT, Xia YL, Liu T, Tse G; International Health
Informatics Study (IHIS) Network. Spontaneous type 1 pattern,
ventricular arrhythmias and sudden cardiac death in Brugada Syndrome:
an updated systematic review and meta-analysis. J Geriatr Cardiol.
2017 Oct;14(10):639-643. doi: 10.11909/j.issn.1671-5411.2017.10.010.
PMID: 29238365; PMCID: PMC5721199.
- Chen C, Tan Z, Zhu W, Fu L, Kong Q, Xiong Q, Yu J, Hong K. Brugada
syndrome with SCN5A mutations exhibits more pronounced
electrophysiological defects and more severe prognosis: A
meta-analysis. Clin Genet. 2020 Jan;97(1):198-208. doi:
10.1111/cge.13552. Epub 2019 May 6. PMID: 30963536.
- Probst, V., Veltmann, C., Eckardt, L., Meregalli, P. G., Gaita, F.,
Tan, H. L., Wilde, A. A. (2010). Long‐term prognosis of patients
diagnosed with Brugada syndrome: Results from the FINGER Brugada
Syndrome Registry. Circulation , 121 (5), 635–643.
https://doi.org/10.1161/circulationaha.109.887026.
- Rattanawong P, Chenbhanich J, Mekraksakit P, Vutthikraivit W,
Chongsathidkiet P, Limpruttidham N, Prasitlumkum N, Chung EH. SCN5A
mutation status increases the risk of major arrhythmic events in Asian
populations with Brugada syndrome: systematic review and
meta-analysis. Ann Noninvasive Electrocardiol. 2019 Jan;24(1):e12589.
doi: 10.1111/anec.12589. Epub 2018 Aug 20. PMID: 30126015; PMCID:
PMC6931443.